Reviewing Telomir Pharmaceuticals (TELO) & Its Competitors

Telomir Pharmaceuticals (NASDAQ:TELO) is one of 1,072 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Telomir Pharmaceuticals to related companies based on the strength of its earnings, profitability, institutional ownership, analyst recommendations, valuation, risk and dividends.

Earnings and Valuation

This table compares Telomir Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	-$16.53 million	-5.05
Telomir Pharmaceuticals Competitors	$9.89 billion	$136.37 million	-3.96

Telomir Pharmaceuticals’ competitors have higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Telomir Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-1,170.58%	-832.67%
Telomir Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Volatility and Risk

Telomir Pharmaceuticals has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals’ competitors have a beta of 3.86, indicating that their average stock price is 286% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Telomir Pharmaceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	0	0	1	1	3.50
Telomir Pharmaceuticals Competitors	8408	22247	50400	1349	2.54

Telomir Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 411.95%. As a group, “Pharmaceutical preparations” companies have a potential upside of 252.08%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Telomir Pharmaceuticals is more favorable than its competitors.

Institutional & Insider Ownership

44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Telomir Pharmaceuticals competitors beat Telomir Pharmaceuticals on 9 of the 13 factors compared.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.